<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Cardiovascular Safety of Linagliptin Demonstrated in Pooled Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-22</style></pages><abstract><style  face="normal" font="default" size="100%">The cardiovascular (CV) safety of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus has been supported by a pooled comprehensive analysis of prospectively adjudicated CV events in Phase 3 studies. CV benefit with linagliptin is being tested prospectively in the CAROLINA study [NCT01243424] against glimepiride and in the CARMELINA study [NCT01897532] against placebo. The pooled analysis included 9459 patients from 19 United States or multinational, multicenter, double-blind, parallel-group studies.</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>